Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Clinical Breast Cancer|March 8, 2021
Development of a Prognostic Factor Index Among Women With HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer in a Community Oncology SettingGregory A Vidal, Gebra Cuyun Carter, Adrienne M Gilligan, et al.
JAMA Network Open|June 27, 2024
Remote Monitoring App for Endocrine Therapy Adherence Among Patients With Early-Stage Breast Cancer: A Randomized Clinical TrialIlana Graetz, Xin Hu, Mehmet Kocak, et al.
Clinical Lung Cancer|December 23, 2022
27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer StudyDavid L Saltman, Matthew G Varga, Tyler J Nielsen, et al.
Proceedings (Baylor University. Medical Center)|July 18, 2020
Usefulness of patient-reported outcomes to assess the effectiveness of topical hormonal therapy for gynecologic symptoms after antihormonal treatment for breast cancerAmit L Jain, Omer Jamy, Janice Mullins, et al.
BMC Cancer|April 15, 2022
Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancerHarsha Ranganath, Amit L Jain, Justin R Smith, et al.
Contemporary Clinical Trials|December 18, 2023
Advancing Inclusive Research (AIR) Site Alliance: Facilitating the inclusion of historically underrepresented people in oncology and ophthalmology clinical researchGregory A Vidal, Patricia Chalela, Andrea N Curry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2024
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO GuidelineNadine Tung, Charité Ricker, Hans Messersmith, et al.
NPJ Breast Cancer|October 5, 2024
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancerAnthony D Elias, Alyse W Staley, Monica Fornier, et al.
Cancer Research Communications|August 22, 2024
Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed TherapyElisabeth Heath, Gregory Dyson, Jennifer R Ribeiro, et al.
NPJ Breast Cancer|May 20, 2023
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancerAnthony D Elias, Nicole S Spoelstra, Alyse W Staley, et al.
Pageof 5